golden empire jili hack
2025-01-08

( MENAFN - GetNews) Millimeter wave (mmWave) innovation and a small float spark investor excitement as Peraso Inc. (NASDAQ: PRSO) captures attention in the drone tech space. Peraso Inc. (NASDAQ: PRSO) , a leader in millimeter wave (mmWave) technology, is making headlines with its cutting-edge innovations in wireless connectivity, specifically for surveillance drones. Leveraging high-speed, low-latency links, Peraso's technology is ideal for drones that require real-time data transfer, making it a game-changer in sectors like security, logistics, and remote monitoring. With a remarkably low float of just 3.9 million shares , Peraso Inc. (NASDAQ: PRSO) has become a high-potential stock to watch. To put this in perspective, the float is nearly 20 times smaller than that of Ondas Holdings Inc. (NASDAQ: ONDS) , which recently experienced a massive rally, climbing from $0.80 to $1.50 in a matter of weeks. This kind of volatility could signal a similar breakout opportunity for Peraso. The global drone market continues to expand at an unprecedented pace, driven by demand for advanced applications in both civilian and military sectors. Peraso's mmWave technology is uniquely positioned to serve this booming market, as it provides the ultra-fast data speeds and minimal latency essential for drones used in real-time surveillance, precision delivery, and beyond. Investors are Taking Note The combination of a small float, advanced technology, and growing market demand has led to increased interest from retail and institutional investors alike. Stocks with a limited float like Peraso Inc. (NASDAQ: PRSO) often see significant price movements when demand spikes, offering the potential for sharp gains in a short timeframe. Analysts Are Watching the Drone Boom The adoption of mmWave technology is becoming a cornerstone of the next generation of drone communication systems. With industries increasingly turning to autonomous solutions, companies like Peraso Inc. (NASDAQ: PRSO) are set to ride the wave of this transformation. As Peraso Inc. (NASDAQ: PRSO) continues to innovate and expand its influence in the drone tech sector, all eyes are on Peraso Inc. (NASDAQ: PRSO) as a potential breakout stock. With its affordable price point , compelling technology, and bullish market indicators, this is one ticker investors won't want to miss tuned for updates as the drone mystery unfolds and Peraso Inc. (NASDAQ: PRSO makes its mark in the world of advanced mmWave technology stocks in the drone sector, including Peraso Inc. (NASDAQ: PRSO), Joby Aviation Inc. (NYSE: JOBY), Archer Aviation Inc. (NYSE: ACHR), Unusual Machines Inc. (NYSE: UMAC), Mobilicom Limited (NASDAQ: MOB), and Ondas Holdings Inc. (NASDAQ: ONDS) , have demonstrated notable momentum and deserve a spot on every investor's radar. Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website. MENAFN16122024003238003268ID1108999899 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.NOVATO, Calif. , Dec. 11, 2024 /PRNewswire/ -- Hennessy Advisors, Inc. (Nasdaq: HNNA) today reported results for the fiscal year ended September 30, 2024 . "So far in 2024, the U.S. stock market and economy have thrived on a wave of optimism," said Neil Hennessy , Chairman and CEO. "With the presidential election and initial Federal Reserve rate cuts now behind us, investors can return their focus to core fundamentals of the U.S. economy, which appear solid." "Over the course of more than four decades in this business, I have witnessed the economic resilience of the United States through periods of high inflation, rising interest rates, and geopolitical uncertainty. Today, I believe many economic fundamentals are strong. Unemployment is low and stable, corporate earnings and cash flows are robust, and our banking system is both healthy and viable. With positive consumer sentiment, I see spending driving corporate profits, and I believe this will spur the stock market's continued growth through the end of the year and beyond. As always, our focus remains on navigating any economic environment to deliver long-term value for our shareholders," he continued. "In the one-year period ended September 30, 2024 , the Dow Jones Industrial Average returned 28.85% and the S&P 500 ® Index returned 36.35% (on a total return basis). Over the same period, all 17 Hennessy Funds posted positive returns. Over the longer term, 15 of the Hennessy Funds posted positive returns for the three-year period ended September 30, 2024 , and all 16 Hennessy Funds with at least 10 years of operating history posted positive returns for both the 5-year and 10-year periods ended September 30, 2024 ," stated Neil Hennessy . "In 2024, we successfully executed on all three fronts of our long-standing business strategy," said Teresa Nilsen , President and COO. "Over the twelve months ended September 30, 2024 , we purchased assets related to the management of $72 million in mutual funds, we welcomed $549 million in net new assets under management, and we benefited from nearly $1 billion in market appreciation." "The effective execution of our business model drove a 23% increase in our average assets under management over the prior year, creating a strong start to fiscal year 2025 with total assets under management up more than 50% since September 30, 2023 ," she continued. "Our fiscal year results reflect both the strength of our consistent strategy and the dedication of our talented team, whose focused efforts have driven the success of Hennessy Advisors for over 35 years. I am immensely proud of what we've accomplished and excited about the opportunities that lie ahead." Summary Highlights for the Fiscal Year (compared to fiscal year 2023): Twelve Months Ended Sept 30, Change 2024 2023 Dollar Percent Total Revenue $ 29,646,194 $ 24,019,874 $ 5,626,320 23.4 % Net Income 7,096,701 4,770,888 2,325,813 48.8 % Earnings Per Share (Diluted) 0.92 0.63 0.29 46.0 % Weighted Average Number of Shares Outstanding (Diluted) 7,721,781 7,603,676 118,105 1.6 % Average Assets Under Management 3,686,942,501 2,991,689,979 695,252,522 23.2 % As of Sept 30, 2024 2023 Total Assets Under Management $ 4,642,363,105 $ 3,032,041,791 $ 1,610,321,314 53.1 % Cash and Cash Equivalents, Net of Gross Debt Balance 23,671,594 20,225,668 3,445,926 17.0 % About Hennessy Advisors, Inc. Hennessy Advisors, Inc. is a publicly traded investment manager offering a broad range of domestic equity, multi-asset, and sector and specialty funds. Hennessy Advisors, Inc. is committed to providing superior service to shareholders and employing a consistent and disciplined approach to investing based on a buy‐and‐hold philosophy that rejects the idea of market timing. Supplemental Information Nothing in this press release shall be considered a solicitation to buy or an offer to sell a security to any person in any jurisdiction where such offer, solicitation, purchase, or sale would be unlawful under the securities laws of such jurisdiction. Forward-Looking Statements This press release contains "forward-looking statements" for which Hennessy Advisors, Inc. claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995. Forward‐looking statements relate to expectations and projections about future events based on currently available information. Forward‐looking statements are not a guarantee of future performance or results and are not necessarily accurate indications of the times at which, or means by which, such performance or results may be achieved. Forward‐looking statements are subject to risks, uncertainties, and assumptions, including those described in the sections entitled "Risk Factors" and elsewhere in the reports that Hennessy Advisors, Inc. files with the Securities and Exchange Commission. Unforeseen developments could cause actual performance or results to differ substantially from those expressed in, or suggested by, the forward‐looking statements. Hennessy Advisors, Inc. management does not assume responsibility for the accuracy or completeness of the forward-looking statements and undertakes no responsibility to update any such statement after the date of this press release to conform to actual results or to changes in expectations. View original content: https://www.prnewswire.com/news-releases/hennessy-advisors-inc-reports-46-increase-in-annual-earnings-per-share-302329179.html SOURCE Hennessy Advisors, Inc.
In recent years, with the ongoing advancements of new technology, more content creators have been developing online personas to attract and interact with viewers, as seen with the growing number of virtual YouTubers, or VTubers. Some may use this technology to create a recognizable mascot character or to separate their real and online identities. Others, lacking self-confidence, might hide behind a fictional representation. However, there are also some people who use AR and AI technology to deceive others. In early 2024, Kaiga Yokota, a 33-year-old resident of Moriguchi, Osaka, used AI to design a character so realistic that it could be mistaken for a real woman. He proceeded to set up social media accounts and pose as this woman online, advertising his services to help people become more attractive to the opposite sex. At this stage, while his actions may be dishonest, it’s hard to say they were inherently illegal. He was simply a man using a symbol to conduct his business. The same could easily be said for VTubers. By June 2024, the social media page of Yokota’s online personality, going by the name of Miru Nanase, had amassed approximately 90,000 followers. He offered people the chance to become more appealing to the opposite sex by transforming their appearance, personality, and communication skills. Many people were interested in the services, but appointments had to be made by signing up through the LINE messaging app. However, the lack of responses to comments from interested users and the absence of testimonials led many to question the legitimacy of the business and even the existence of Miru Nanase. On December 5, Yokota was arrested on suspicion of fraud. The allegations state that between April 16 and May 6, he swindled a total of 1.25 million yen from a 35-year-old man living in Yamato-Takada City, Nara Prefecture. The money was paid with the expectation of receiving advice on attracting women and as investment funds for forex trading. Yokota has not disputed the transaction but claims that there was no deception involved. Setting aside the questionable logic of paying a stranger on social media substantial sums of money for dating advice — not once, but three whole times, it’s currently unclear whether the prosecution’s case will hinge entirely on Yokota’s use of the AI-generated images and persona to present the advice as coming from an attractive woman, or if the accusations are more related to possible non-delivery of actual dating advice. Either way, like our lonely man from Nara learned, we should approach internet interactions with a healthy dose of skepticism and remember that online actions can sometimes have real consequences. Source: Mainichi Shimbun via Hachimakiko Read more stories from SoraNews24. -- Japanese communications company to introduce AI love advice specialist -- AI Samurai: The artificially intelligent, armored samurai that will answer all your questions -- Tokyo government’s official AI-powered dating app, Tokyo Enmusubi, has officially launchedThe U.S. Commerce Department is intensifying its scrutiny on China Telecom's American operations, amid fears of potential misuse of access to U.S. data for the benefit of Beijing. This action follows the department's issuance of a preliminary determination indicating the risks to national security posed by the company. A reliable source has confirmed that the department's decision stems from last week's report by the New York Times, which highlighted these concerns linked to China Telecom and its integration in U.S. networks and cloud services. The company has been granted a 30-day period to counter the department's national security risk claims, as the apprehension over potential data leakage to China increases tension in international business relations. (With inputs from agencies.)
By Michelle Marchante, Miami Herald (TNS) MIAMI — As her students finished their online exam, Arlet Lara got up to make a cafe con leche . Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. “I had a stroke and my life made a 180-degree turn,” Lara told the Miami Herald, recalling the medical scare she experienced in May 2020 in the early months of the COVID pandemic. “The stroke affected my left side of the body,” the North Miami woman and former high school math teacher said. Lara, an avid runner and gym goer, couldn’t even walk. “It was hard,” the 50-year-old mom said. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. This first procedure was at Jackson Memorial Hospital in Miami. Lara’s rehab was at at the Christine E. Lynn Rehabilitation Center for The Miami Project to Cure Paralysis, part of a partnership between Jackson Health System and UHealth. Every year, thousands in the United States have a stroke , with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System, the device implanted in Lara’s chest, could be a game changer in recovery, said Dr. Robert Starke, a UHealth neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, part of Miami-Dade’s public hospital system. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant designed to help stroke survivors regain function in their arms, goes through exercises while her therapist activates the device during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA- approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration approved the stroke rehabilitation system in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara’s occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body’s nervous system. The electrical stimulation rewires the brain to improve a stroke survivor’s ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. “Little by little, I’m noticing that my hand is getting stronger. I am already able to brush my teeth with the left hand,” she told the Miami Herald in September. Since then, Lara has finished the initial six-week Vivitism therapy program, and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Lara learned about the device through an online group for stroke survivors and contacted the company to inquire. She then connected them with her Jackson medical team. Now a year later, the device is available to Jackson patients. So far, four patients have received the implant at Jackson. Related Articles Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors can usually recover some function through treatment and rehabilitation, they tend to hit a “major plateau” after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal The Lancet in 2021 showed that the device, “when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone.” The device has even shown to benefit patients 20 years from their original stroke, according to Starke. “So now a lot of these patients that had strokes 10-15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous,” Starke said. Vivistim’s vagus-nerve stimulation technology was developed by researchers at the University of Texas at Dallas’ Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to treat epilepsy and depression . For Lara, the device is a new tool to help her recovery journey. “Everything becomes a challenge so we are working with small things every day because I want to get back as many functions as possible,” Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history, including concurrent forms of brain stimulation, current diathermy treatment, previous brain surgery, depression, respiratory diseases and disorders such as asthma, and cardiac abnormalities. “Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue,” the FDA said. MicroTransponder says the device is “covered by Medicare, Medicaid, and private insurance with prior authorization on a case-by-case basis.” To learn more about the device, visit vivistim.com. ©2024 Miami Herald. Visit at miamiherald.com. Distributed by Tribune Content Agency, LLC.Haiti’s children ‘dragged into hell’ as gang violence rages
Wild first season in expanded Big 12 comes down to final weekendFormer Presidential Candidate Marianne Williamson Launches Bid for DNC Chair
Related hot word search:
Previous: golden empire jili game
Next: